Panacea Biotec joins EU consortium to test dengue vaccine in Africa
The €11.1 million project will run Phase I/III trials of the single-dose DengiAll vaccine in sub-Saharan Africa. The grant goes to the consortium, not Panacea.
— 1 earlier story on Panacea Biotec Ltd. →What's new
- Panacea Biotec has joined the DENSTAR consortium to advance its dengue vaccine toward African licensure.
- The €11.1 million project will fund Phase I/III trials of DengiAll in sub-Saharan African adults and children.
- It will test efficacy against the DENV-4 serotype using controlled human infection models.
Why this matters
This opens a potential regulatory path in a high-burden region for Panacea's lead pipeline asset. The catch is the money. The grant flows to the ten-partner consortium, not to Panacea's balance sheet. There are no direct financial commitments or revenue projections for the company.
What we're watching
- Phase I/III trial timelines and enrollment progress in sub-Saharan Africa.
- Panacea's ability to fund late-stage development independently or through new partnerships.
- Regulatory submissions in African countries once trial data is available.
The full read
Panacea Biotec has joined a €11.1 million EU-funded consortium to push its dengue vaccine toward African licensure. The four-year DENSTAR project will run Phase I/III trials of the single-dose DengiAll vaccine in sub-Saharan African adults and children. A specific goal is testing efficacy against the DENV-4 serotype using controlled human infection models, where no vaccine has proven protection yet. For a small-cap biotech, this is a significant step for a pipeline asset already in late-stage development in India. The grant, however, is a consortium award. It is not direct funding for Panacea. The filing contains no revenue projections or financial commitments to the company. The vaccine's path to market just got a potential new geography. The path to Panacea's bank account remains unclear.
Questions answered
- What is DengiAll and what makes it different?
- DengiAll is a single-dose, tetravalent live-attenuated vaccine targeting all four dengue serotypes. The consortium will specifically test its efficacy against DENV-4, a serotype for which no vaccine has shown protection in controlled human infection models.
- Who gets the €11.1 million grant?
- The grant is awarded to the DENSTAR consortium as a whole, coordinated by Italy's Sclavo Vaccines Association. Panacea is one of ten partners and will supply the vaccine and support studies, but the funding is not paid directly to the company.
- Does this have a near-term financial impact for Panacea?
- No. The filing states there are no quantified financial commitments or revenue projections for Panacea. The project is in early clinical stages, and the grant supports the consortium's work rather than Panacea's P&L.
- What is Panacea's role in the project?
- As the vaccine developer, Panacea will supply the DengiAll vaccine and support the clinical studies. It is one of ten partners from Europe, Africa, the US, India, and South Korea.
Story so far
All notes on PANACEABIO →- 8 Jun 2026 · 6:24 PM IST Panacea Biotec joins EU consortium to test dengue vaccine in Africa
- 9d ago Panacea Biotec reports widening losses as auditors flag stability